Literature DB >> 6990961

Terminal transferase enzyme assay and immunological membrane markers in the diagnosis of leukaemia: a multiparameter analysis of 300 cases.

G Janossy, A V Hoffbrand, M F Greaves, K Ganeshaguru, C Pain, K F Bradstock, H G Prentice, H E Kay, T A Lister.   

Abstract

Multiparameter analyses have been carried out with recently developed enzyme and membrane markers in 300 patients with various leukaemias including ALL, AML, but excluding Ph1 positive leukaemias. TdT enzyme levels were particularly valuable in the differential diagnosis of adult acute lymphoid and myeloid leukaemias. The levels were raised in 108 (94%) of the 115 patients who were considered to be non-T, non-B ALL on membrane marker and morphological analysis; all seven cases giving negative TdT results in this group were young children. Unexpectedly high levels were seen only in three (4.1%) of 73 cases of acute myeloid leukaemia verified by histochemistry and membrane markers. Anti-ALL serum was a most useful reagent in childhood leukaemias but blasts from 19 patients (10% of childhood ALL cases and 29% of adult ALL cases) failed to react with the serum in spite of TdT positivity. Strongly ALL+ blasts were seen only in non-T, non-B ALL and some undifferentiated leukaemias. Weakly ALL+ blasts were seen in seven of 32 cases of thymic ALL (Thy-ALL) but in other respects these blasts expressed Thy-ALL features, such as strong reactivity with anti-T cell (HuTLA) serum, negativity with anti-Ia-like serum and raised TdT. The combination of tests was particularly useful in 32 cases of undifferentiated leukaemia: in 10 of these cases TdT positivity indicated the probable 'lymphoblast', nature of blast cells: the remaining 22 cases remained unclassifiable with the markers used. The analysis revealed other interesting variant forms of leukaemias.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6990961     DOI: 10.1111/j.1365-2141.1980.tb01204.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  17 in total

1.  Monoclonal antibody (WT 1) directed against a T cell surface glycoprotein: characteristics and immunosuppressive activity.

Authors:  W J Tax; N Tidman; G Janossy; L Trejdosiewicz; R Willems; J Leeuwenberg; T J De Witte; P J Capel; R A Koene
Journal:  Clin Exp Immunol       Date:  1984-02       Impact factor: 4.330

2.  Comparison of histologic and immunologic heterogeneity of non-Hodgkin's lymphomas.

Authors:  M J Borowitz; B P Croker; R S Metzgar
Journal:  Am J Pathol       Date:  1981-11       Impact factor: 4.307

3.  Beckwith-Wiedemann (exomphalos-macroglossia-gigantism--EMG) syndrome and malignant lymphoma.

Authors:  A H Wojciechowski; J Pritchard
Journal:  Eur J Pediatr       Date:  1981-11       Impact factor: 3.183

Review 4.  Some aspects of immunological and cytochemical markers in leukemia.

Authors:  D Huhn
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

Review 5.  Biochemical enzyme analysis in acute leukaemia.

Authors:  H G Drexler; G Gaedicke; J Minowada
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

6.  Routine flow cytometric diagnosis of lymphoproliferative disorders.

Authors:  I G Barr; B H Toh
Journal:  J Clin Immunol       Date:  1983-04       Impact factor: 8.317

7.  Analysis of the binding of peanut agglutinin (PNA) to leukaemic cells and its relationship to T-cell differentiation.

Authors:  R A Newman; D Delia
Journal:  Immunology       Date:  1983-05       Impact factor: 7.397

8.  Diagnostic specificity of the monoclonal anti-CALLA antibody VIL-A1 in leukemia and malignant lymphoma.

Authors:  W Knapp; D Lutz; P Bettelheim; T Radaszkiewicz; O Majdic; H Gadner
Journal:  Med Oncol Tumor Pharmacother       Date:  1984

Review 9.  Childhood acute lymphocytic leukemia: progress and problems in treatment.

Authors:  W P Bowman
Journal:  Can Med Assoc J       Date:  1981-01-15       Impact factor: 8.262

Review 10.  Enzyme and membrane markers in leukaemia: recent developments.

Authors:  A V Hoffbrand; G Janossy
Journal:  J Clin Pathol       Date:  1981-03       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.